Seroquel XR in the Long Term Treatment of Schizophrenia

Seroquel XR in the Long Term Treatment of Schizophrenia Focus on Affective Symptoms

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01202617

Acronym

SereNIS

Enrollment

1606

Registered

2010-09-16

Start date

2010-09-30

Completion date

2011-10-31

Last updated

2011-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapse in Schizophrenia

Keywords

Seroquel XR, schizophrenia, relapse prevention

Brief summary

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion criteria

* Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity

Design outcomes

Primary

Measure	Time frame
Rate of patients remained relapse free after 6 months of treatment	on the 60th day of treatment

Secondary

Measure	Time frame
connection between relapse and affective symptoms	on the 60th day of treatment

Countries

Hungary

Outcome results